Radiopharmaceuticals
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network
Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal
Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings
ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing
ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal
RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
Novartis Invests $180M in PeptiDream to Boost Radiopharmaceutical Development
Novartis, PeptiDream, radiopharmaceuticals, investment, drug development, partnership, targeted therapies, cancer treatment, radioactive isotopes.